Randomized Trialmoderate evidence
Nonsedating neurotransmitter-modulating supplement for nonvasomotor sleep disturbance in menopause.
Menopause (New York, N.Y.)·September 15, 2026·PMID 42742055
Why it mattersSleep disturbance is common in menopause even without vasomotor symptoms, yet treatment options are limited. This supplement offers a potential nonhormonal, nonsedating approach that improved both subjective and objective sleep measures in a well-designed trial.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled